bullish

Zydus Lifesciences: High Base to Keep EPS Muted, Specialty Growth Key. Maintain ADD

258 Views11 Nov 2024 17:36
Broker
Zydus Life has corrected over 25% from its 52-week high in the last 2-3 months, due to (1) competition in gAsacol HD (Teva, launched in Sep ’24)
What is covered in the Full Insight:
  • 1. Introduction to Zydus Lifesciences
  • 2. Recent Stock Performance and Challenges
  • 3. Future Growth Prospects and Projections
  • 4. Key Developments in the US and India Markets
  • 5. Conclusion and Investment Insights
SUMMARY
(Sign Up to Access)
Full Insight
(Paid Plans Only, 26-minute read)
Discussions
(Paid Plans Only)
chart-bar
Price Chart(Sign Up to Access)
analytics-chart
  • Zydus Lifesciences: High Base to Keep EPS Muted, Specialty Growth Key. Maintain ADD
    11 Nov 2024
x